



20 Years of Excellence in
Public Health Implementation,
Capacity Building and Research



IHVN AT A GLANCE



IHVN Board and Management cut the cake in commemoration of the Institute's 20th anniversary

The Institute of Human Virology, Nigeria (IHVN) is a non-governmental organisation established in 2004 to address the HIV/AIDS crisis in Nigeria by developing infrastructure for treatment, care, prevention, and support for people living with and affected by HIV/AIDS. IHVN has expanded its services to other infectious diseases like tuberculosis, malaria and non-infectious diseases, including cancers.

As a local organization, the Institute is structured to collaboratively develop and maintain linkages within and outside the country that support the Government of Nigeria's health sector strategic plans. IHVN's critical technical and funding partners include the Centers for Disease Control and Prevention (CDC), the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States Agency for International Development (USAID)

ASPIRE: The ACTION to Sustain Precision and Integrated HIV Response towards Epidemic Control (ASPIRE) project is funded by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the US Centers for Disease Prevention and Control (CDC). The project focuses on Nasarawa State, Rivers State, Katsina State, and the Federal Capital Territory (FCT). Amongst other areas, the ASPIRE project aims to reduce the mortality of people living with HIV (PLHIV) by providing services to know their HIV status and be linked to quality sustained treatment. ASPIRE project provides the following services in the health facilities we support: HIV Testing Services (HTS), laboratory diagnosis and tracking of status of people living with HIV, Prevention of Mother-to-Child Transmission (PMTCT) of HIV, Anti-retroviral Treatment (ART) for adult and children (including pregnant women), care and support for people living with HIV/AIDS and people affected by HIV/AIDS, monitoring and evaluation of patients and program progress, support to Orphans and Vulnerable Children (OVC), Gender-Based Violence (GBV) support services and training in all the above areas. As of June 2024, 598,055 patients received ARV drugs and treatment under this project.

RESEARCH and TRAINING: IHVN has established a center, the International Research Center of Excellence (IRCE) to promote public/private partnerships for quality health services, capacity building, and research in West Africa. IHVN, through IRCE, aims to foster collaboration between

scientists both international and local healthcare providers, the government of Nigeria, and the communities it serves. IRCE has gradually expanded its research portfolio to include other infectious diseases such as Tuberculosis (TB), Malaria, viral Hepatitis, COVID-19, Monkey Pox, emerging viral infections, and other non-communicable diseases. This diversification has allowed the center to contribute towards understanding and controlling infectious and non-infectious diseases. As of June 2024, 114,602 healthcare professionals have been trained in HIV, TB, and other areas.

Global Fund is a combined effort for tuberculosis (TB) and HIV and is pivotal for the transformation of TB and HIV programs. Under the guidance of the National AIDS and STDs Control Programme (NASCP), the National TB and Leprosy Control Programme (NTBLCP), and the National Agency for the Control of AIDS (NACA), this project aims to increase the identification of all forms of TB in both the private sector and the community. The Country Coordinating Mechanism for the Global Fund (CCM) has oversight functions to support the smooth implementation of the grant.











The GC7 project is focused on ensuring early diagnosis of TB and HIV and providing comprehensive care for affected individuals. It runs from January 2024 to December 2026 and will increase the provision of tuberculosis services in the community through

public-private partnerships. Other grant objectives include expanding HIV testing for all pregnant women in communities and strengthening laboratories and supply chain management.

Prior to the GC7 project IHVN implemented the TB Public Private Mix Scale-up project as Principal Recipient from January 2019 to March 2023. During that period, 175,867 TB cases were notified by non-national TB program providers. In addition, a Drug-resistant tuberculosis (DR-TB) program as implemented from June 2011 to December 2018 and it identified 9,036 drug-resistant tuberculosis cases and enrolled 6,515 drug-resistant

tuberculosis patients for treatment. IHVN was also a sub-recipient to FHI 360, providing HTS, PMTCT, ART and TB/HIV services in ten states.

The USAID Tuberculosis Local Organization Network (TB-LON 3) project is a five-year project to scale up tuberculosis services and find missing TB cases. It started in April 2020 and engaged stakeholders in strengthening a resilient system for sustainable TB control in Lagos, Ogun, Oyo and Osun states. As of June 2024, 111,254 tuberculosis cases were identified, notified and treated.

IHVN ACHIEVEMENTS FROM 2004 to June 2024			
	PEPFAR Funded (ACTION, ACTIONPlus, ACTION PlusUp, ACHIEVE & ASPIRE Projects)	Global Fund HIV (Project concluded in June 2019)	TOTAL
 Individuals counseled, tested and received results	17,000,022	2,508,810	19,508,832
 Pregnant women counseled, tested and received results	4,146,637	1,550,279	5,696,916
 Pregnant women confirmed positive	119,331	21,679	141,010
 Pregnant women provided anti-retroviral prophylaxis	111,423	18,152	129,575
 Clients cumulatively enrolled in the HIV care program	700,234	104,837	805,071
 Clients cumulatively initiated on ART	598,055	99,262	697,317
 Pediatric clients cumulatively initiated (subset of ART above)	23,483	39,849	63,332
 Clients provided TB treatment	53,009	2,851	55,860
 Number of Orphans and Vulnerable children (OVC) cared for	228,201	N/A	228,201
 Number of Services Delivery Points	ART:384	ART: 69	453
	PMTCT:369	PMTCT: 347	716
	TB:185	DR-TB:28	213
	HTS:384	HTS:416	800
	OVC:16		16
Number of People Trained		114,602	

Leader in providing quality health services capacity building and research in West Africa